Moreover, due to the highly vascularized nature of both solid tumors, targeted therapies against key pathways in angiogenesis and metastasis, such as vascular endothelial growth factor (VEGF) and its receptors (VEGFR), constitute the standards of treatment for advanced liver and colorectal tumors currently [4,7,8]. The gene discussed is VEGFA; the disease is colorectal neoplasm.